Hormone Replacement Therapy after Prophylactic Adnexectomy by This, Pascale et al.
H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(4) 181
Hereditary Cancer in Clinical Practice 2005; 3(4) pp. 181-182
Hormone Replacement Therapy after Prophylactic Adnexectomy
Pascale This, Rémy J. Salmon, Sylvie Dolbeault, Annede la Rochefordière, Brigitte Sigal-Zafrani, Dominique Stoppa-Lyonnet, 
on behalf of the Institut Curie Breast and Ovarian Cancer Risk Study Group*
*Members of the Institut Curie Breast and Ovarian Cancer Risk Study Group: Andrieu N, Asselain B, de Cremoux P, de La Rochefordiere A, Dolbeault S, Extra JM,
Fourquet A, Gauthier-Villars M, Meunier M, Salmon RJ, Sigal-Zafrani B, Stoppa-Lyonnet D, Tardivon A, Thibault F, This P
Corresponding author: Dr Pascale This, Institut Curie 26, rue d'Ulm, F-75248 Paris cedex 5, tel. 33 1 44 32 46 47, 
fax 33 1 44 32 45 09, e-mail: pascale.this@curie.net
Submitted: 18 September 2005
Accepted: 25 September 2005
In France, the National Collective Statement from
the  INSERM  [1]  recommends  a prophylactic
adnexectomy (PA) in women having an increased
ovarian cancer risk due to mutations in BRCA1 or
BRCA2 either at 40 years of age or at 35 years of age
if  the  woman  has  decided  she  no  longer  wants
children. PA can reduce the risks of ovarian cancer by
more than 90% and breast cancer by more than 50%.
However, the lack of oestrogen production caused by
PA has numerous consequences. These are more
pronounced in young women and include hot flushes,
vaginal dryness, sexual troubles, joint stiffness and in
the long term osteoporosis. Recent data from the large
randomised American WHI Study [2, 3] have led the
medical community to re-evaluate the benefits and risks
of hormone replacement therapy (HRT) and to modify
their  prescription  practices.  As  data  on  the  HRT
products used in France are not available, French
agencies have recommended that in the general
population HRT should be used at the lowest dose and
for the shortest duration possible, and then only for
menopausal problems [4]. Currently, many women in
France are reluctant to use HRT because of the results
of these studies. Gynaecologists also are reluctant to
prescribe HRT due to the risk of legal proceedings in
cases of cancer. This reluctance is much greater for
women with increased risk of breast cancer. Although
the Markov Model for predisposed women shows
a favourable benefit/risk ratio for short-term HRT
prescription, this analysis was carried out without
precise data for the effect of HRT on predisposed
women  [5].  Moreover,  breast  cancer  in  women
undergoing HRT may be falsely attributed to HRT due
to the high incidence of breast cancer associated with
BRCA1/2 mutations. We have observed that PA is
relatively well accepted in peri-menopausal women (for
example after chemotherapy), although some young
women still refuse or delay PA despite there being
a high incidence of ovarian cancers in their family. 
At the Curie Institute, we take into account the
preferences of women after they have been thoroughly
informed: 
1. We recommend PA to women at 40 years of age if
they have a BRCA1 mutation, or a BRCA2 mutation
and a family history of ovarian cancer, and at 50
years of age if they have a BRCA2 mutation without
a family history of ovarian cancer. 
2. In women unaffected by breast cancer, we give very
complete information on the benefits and risks of
HRT  and  alternatives,  such  as  symptomatic
treatments for hot flushes, vaginal oestrogens, and
non-hormonal treatment for osteoporosis. 
3. We always propose psychological support to allow
each  woman  to  estimate  and  anticipate  the
consequences of PA. 
4. In  case  of  uterine  diseases  such  as  fibroma,
surgeons may propose a hysterectomy as well as
PA, in which case oestrogens can be prescribed
alone and progestins can be avoided (4). 
5. After PA, a gynaecological consultation is offered:
HRT is given only to thoroughly informed women who
really  want  it  and  have  accepted  PA  with  the
assurance that they would have HRT afterwards. HRT
is  also  offered  to  women  who  have  had
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clinical follow-up is proposed, and osteodensitometry
is  prescribed.  If  menopausal  problems  occur,
alternative treatments are proposed first. For persistent
problems, HRT is prescribed at the lowest dose for
as  long  as  the  woman  wishes.  It  is  strongly
recommended that treatment be stopped at the
natural age of menopause, around 50 years of age. 
We  think  that  over-alarmist  information  on
menopause and strongly held beliefs against HRT lead
some young women to refuse or delay an intervention
that may save their life. Therefore, we advocate clear
information, honest dialogue, and shared decision
making with each woman. 
R Re ef fe er re en nc ce es s
1. Eisinger F, Bressac B, Castaigne D, Cottu PH, Lansac J, Lefranc
JP , Lesur A, Nogues C, Pierret J, Puy-Pernias S, Sobol H, Tardivon
A, Tristant H and Villet R. Identification and management of
hereditary predisposition to cancer of the breast and the ovary
(update 2004). Bull Cancer 2004; 91: 219-237. 
2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg
C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson
KC, Kotchen JM and Ockene J; Writing Group for the Women's
Health Initiative Investigators. Risks and benefits of estrogen plus
progestin in healthy postmenopausal women: principal results
From the Women's Health Initiative randomized controlled trial.
JAMA 2002; 288: 321-333. 
3. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA,
Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R,
Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J,
Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller
L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson
J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL,
Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van
Horn L, Wactawski-Wende J, Wallace R and Wassertheil-Smoller
S; Women's Health Initiative Steering Committee. Effects of
conjugated equine estrogen in postmenopausal women with
hysterectomy: the Women's Health Initiative randomized controlled
trial. JAMA 2004; 291: 1701-1712. 
4. ANAES A. Traitements hormonaux substitutifs de la ménopause,
rapport d'orientation, Paris 2004. http://www.anaes.fr
5. Armstrong K, Schwartz JS, Randall T, Rubin SC and Weber B.
Hormone  replacement  therapy  and  life  expectancy  after
prophylactic oophorectomy in women with BRCA1/2 mutations:
a decision analysis. J Clin Oncol 2004; 22: 1045-1054. 